Why the study?
Changing epidemiologic and clinical trends suggest contemporary patients with NVAF may derive lower net clinical benefit from long-term oral anticoagulation than observed in original randomized controlled trials.
The net clinical benefit of oral anticoagulation in contemporary NVAF patients may be lower than historical estimates, highlighting the need for updated risk evaluation methods.
Answers are grounded in this paper and cite their sources.
May warrant caution extrapolating historical OAC benefits to contemporary NVAF; leaves open need for updated risk-benefit thresholds.
The prevalence of atrial fibrillation without rheumatic valvular disease, nonvalvular atrial fibrillation (NVAF), increases with age and independently predicts future stroke and systemic embolism. Randomized controlled trials of long-term oral anticoagulation for NVAF since the 1980s report a 67% risk reduction in stroke and systemic embolism. Data from these trials are used in risk calculators to predict stroke and bleeding; clinicians use these calculators to determine individualized net clinical benefit of oral anticoagulation. Over the past three decades, NVAF stroke rates have declined independent of oral anticoagulation. Newer asymptomatic (subclinical) NVAF populations are being identified, and clinical practice has changed with increasingly older patients (with higher fall and bleeding risk) receiving oral anticoagulation. These trends suggest contemporary patients with NVAF may derive a lower net benefit from oral anticoagulation compared with those in the original randomized controlled trial. Methods that evaluate for and continuously monitor net clinical benefit of oral anticoagulation for contemporary NVAF are necessary.
No takes yet. Share an insight, caveat, or question.
Asinger et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: